Hermes Florez to Economics, Medical
This is a "connection" page, showing publications Hermes Florez has written about Economics, Medical.
Connection Strength
0.129
-
A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print]. J Med Econ. 2015; 18(12):1029-31.
Score: 0.129